GleamWall
中文EN

ALDX Aldeyra Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1341235 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY55.7%
TTM EPS YoY57.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-45.3%
ROA-31.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets18.8%
Debt / equity0.00x
Current ratio5.45x
Interest coverage-21.39x

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$25.66M$48.22M
SG&A expense$9.60M$11.89M
Operating income-$35.27M-$60.12M
Interest expense$1.91M$1.93M
Pretax income$33.85M$55.85M
Income tax$0$1,000
Net income-$33.85M-$55.85M
EBITDA-$35.01M-$59.87M
EPS (basic)-0.56-0.94
EPS (diluted)-0.56-0.94
Weighted avg. shares (diluted)60.06M59.48M
Balance sheet
Cash & equivalents$70.04M$54.53M
Short-term investments$0$46.62M
Current assets$71.78M$104.07M
PP&E, net$0$0
Total assets$72.06M$104.61M
Current liabilities$27.81M$18.60M
Short-term debt$15.25M$31,372
Long-term debt$0$15.00M
Total debt$15.25M$15.03M
Total liabilities$27.81M$33.60M
Shareholders' equity$44.25M$71.00M
Net debt-$54.79M-$39.50M
Shares outstanding60.16M59.65M
Cash flow statement
Operating cash flow-$33.35M-$43.21M
Investing cash flow$47.74M-$44.92M
Financing cash flow$1.12M-$171,422
Depreciation & amortization$251,993$249,623
Stock-based compensation$6.09M$7.97M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.